Pyxis Oncology (PYXS) Expected to Announce Earnings on Tuesday

Pyxis Oncology (NASDAQ:PYXS) will likely be posting its Q1 2025 quarterly earnings results before the market opens on Tuesday, May 13th. Analysts expect Pyxis Oncology to post earnings of ($0.29) per share for the quarter.

Pyxis Oncology (NASDAQ:PYXS) last posted its quarterly earnings data on Tuesday, March 18th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.01. The company had revenue of $16.15 million for the quarter. On average, analysts expect Pyxis Oncology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Pyxis Oncology Trading Down 2.8%

Pyxis Oncology stock opened at $1.06 on Monday. Pyxis Oncology has a twelve month low of $0.83 and a twelve month high of $5.39. The stock’s fifty day simple moving average is $1.05 and its 200-day simple moving average is $1.71. The firm has a market capitalization of $65.66 million, a P/E ratio of -1.03 and a beta of 1.15.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price objective on shares of Pyxis Oncology in a research report on Wednesday, March 19th. Royal Bank of Canada reissued an “outperform” rating and issued a $8.00 target price on shares of Pyxis Oncology in a report on Wednesday, March 19th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $9.00.

Hedge Funds Weigh In On Pyxis Oncology

An institutional investor recently raised its position in Pyxis Oncology stock. Bank of America Corp DE boosted its holdings in Pyxis Oncology, Inc. (NASDAQ:PYXS) by 20.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 53,745 shares of the company’s stock after buying an additional 9,062 shares during the quarter. Bank of America Corp DE owned approximately 0.09% of Pyxis Oncology worth $84,000 at the end of the most recent quarter. Institutional investors and hedge funds own 39.09% of the company’s stock.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.